Acetylsalicylic Acid
| Evidence Level: L5 | Predicted Indications: 54 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Acetylsalicylic Acid |
| DrugBank ID | DB00945 |
| Brand Names (EU) | Acetylsalicylic acid, Clopidogrel / Acetylsalicylic acid Viatris (previously Clopidogrel / Acetylsalicylic acid Mylan), Clopidogrel/Acetylsalicylic acid Zentiva (previously DuoCover), DuoPlavin |
| Evidence Level | L5 |
| Predicted Indications | 54 |
| Top Prediction Score | 99.94% |
Approved Indication (EMA)
Acute Coronary Syndrome Myocardial Infarction
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | migraine disorder | 99.94% | DL |
| 2 | migraine with brainstem aura | 99.94% | DL |
| 3 | migraine with or without aura, susceptibility to | 99.78% | DL |
| 4 | atrophoderma vermiculata | 99.59% | DL |
| 5 | ulerythema ophryogenesis | 99.45% | DL |
| 6 | headache disorder | 99.44% | DL |
| 7 | heparin cofactor 2 deficiency | 99.41% | DL |
| 8 | factor 5 excess with spontaneous thrombosis | 99.40% | DL |
| 9 | antithrombin deficiency type 2 | 99.40% | DL |
| 10 | trigeminal autonomic cephalalgia | 99.40% | DL |
| 11 | thrombotic disease | 99.14% | DL |
| 12 | thrombophilia | 99.04% | DL |
| 13 | rheumatoid arthritis | 98.84% | DL |
| 14 | Raynaud disease | 98.67% | DL |
| 15 | non-inflammatory vasculopathy | 98.51% | DL |
| 16 | angiodysplasia | 98.42% | DL |
| 17 | fibrocartilaginous embolism | 98.34% | DL |
| 18 | venous thromboembolism | 98.34% | DL |
| 19 | vein disease | 98.34% | DL |
| 20 | brachydactyly-syndactyly syndrome | 98.27% | DL |
Showing top 20 of 54 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.